The Week in Review: January 23-27 - Psychiatric Times
This week, Psychiatric TimesTM covered a wide variety of psychiatric issues and industry updates, from special issues in diagnosing and treating catatonia to helping justice-involved individuals re-enter the community. Here are some highlights from the week.
FDA Announces Need for New Regulatory Pathway for CBD
The US Food and Drug Administration (FDA) announced that a new regulatory pathway for cannabidiol (CBD) products is needed.
According to the statement—attributed to Janet Woodcock, MD, principal deputy commissioner for the FDA—careful review by an internal FDA working group concluded that the public’s desire for access to CBD products needs to be balanced with the regulatory oversight to help manage and prevent risks associated with use of CBD products. Continue Reading
The Many Faces of Catatonia, An Under-Recognized Clinical Syndrome
Catatonia is a distinct syndrome marked by a heterogenous constellation of hallmark signs and symptoms. It is associated with both psychiatric etiologies, known as primary catatonia, as well as with other neuromedical conditions, or secondary catatonia.
Catatonia was first described by Karl Kahlbaum in 1874, and unfortunately it was nosologically associated primary with schizophrenia syndromes until as recently as the 1990s. We now know that, among primary psychiatric causes of catatonia, mood disorders such as bipolar disorder and major depressive disorder are much more commonly associated. Continue Reading
Positive Results from...
source: https://news.google.com/__i/rss/rd/articles/CBMiRmh0dHBzOi8vd3d3LnBzeWNoaWF0cmljdGltZXMuY29tL3ZpZXcvdGhlLXdlZWstaW4tcmV2aWV3LWphbnVhcnktMjMtMjfSAQA?oc=5
